CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | |
| 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | |
| 4 Filing | 2026-01-26 | English | |
| 4 Filing | 2026-01-05 | English | |
| 4 Filing | 2026-01-05 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 9417631 | FORM 8-K | 2025-11-24 | English | ||
| 9417632 | FORM S-3 | 2025-11-07 | English | ||
| 9417635 | FORM 8-K | 2025-11-05 | English | ||
| 9417633 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
| 9417634 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CHIMERIC THERAPEUTICS LIMITED
Clinical-stage cell therapy company developing CAR T and NK…
|
CHM | AU | Professional, scientific and te… |
|
China National Electric Apparatus Research Institute Co., Ltd.
R&D institution for electrical and electronics testing, equ…
|
688128 | CN | Professional, scientific and te… |
|
Chiome Bioscience Inc.
Clinical-stage biotech company developing antibody-based th…
|
4583 | JP | Professional, scientific and te… |
|
CHITOGENX INC
Clinical stage regenerative medicine company focused on nov…
|
CHGX | CA | Professional, scientific and te… |
|
Chordate Medical Holding AB
Develops a patented, drug-free neuromodulation treatment fo…
|
CMH | SE | Professional, scientific and te… |
|
Chordia Therapeutics,Inc
Clinical-stage biotech developing novel cancer therapies ta…
|
190A | JP | Professional, scientific and te… |
|
Cibus, Inc.
Develops and licenses plant traits using non-GMO precision …
|
CBUS | US | Professional, scientific and te… |
|
Circio Holding ASA
Clinical-stage company developing circular RNA medicines an…
|
CRNA | NO | Professional, scientific and te… |
|
CIZZLE BIOTECHNOLOGY HOLDINGS PLC
A cancer diagnostics developer creating a blood test for ea…
|
CIZ | GB | Professional, scientific and te… |
|
CJ Bioscience
Develops microbiome therapeutics for oncology and IBD using…
|
311690 | KR | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.